The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | The value of axi-cel as a second-line treatment in R/R LBCL
Paolo Cortesi, MD, University of Milan-Bicocca, Milan, Italy, discusses the therapeutic efficacy and cost-effectiveness of CAR-T immunotherapy axicabtagene ciloleucel (axi-cel) for the treatment of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Second-line administration of axi-cel is efficacious for improved survival and quality of life in patients with LBCL, particularly in comparison to standard-of-care (SoC) regimens. Dr Cortesi emphasizes the economic and therapeutic value of second-line axi-cel therapy, in light of its current approval as a third-line immunotherapeutic, and suggests that earlier axi-cel administration may feasibly offset the cost of prospective, continued treatment of patients with LBCL. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Honoraria; Roche: Honoraria; Almirall: Honoraria; Otsuka: Honoraria.
